News
-
DSM And DecImmune Therapeutics Sign Agreement To Develop N2 Pathway Blocking Antibody
4/22/2013
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, announced recently that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.
-
Piramal Enterprises’ Diagnostic Division Launches QDx Instacheck
3/19/2013
Piramal Enterprises’ diagnostic division recently announced the launch of “QDx Instacheck” Right-here-Right-now.
-
INC Research Appoints James Taylor Vice President, Clinical Development
3/18/2013
INC Research, LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced James Taylor has joined the Company as Vice President, Clinical Development. Mr. Taylor joins INC Research from Pfizer, where he served most recently as Vice President, Global Clinical Trial management. In his new role, Mr. Taylor will serve as the primary liaison to biopharmaceutical customers, vendors and investigative sites for the Company's General Medicine Business Unit.
-
Spanish Biotech PharmaMar Selects Medidata Clinical Cloud To Accelerate Trials For Marine-Based Oncology Drugs
3/18/2013
PharmaMar, a Spanish biopharmaceutical company, has selected Medidata Solutions (NASDAQ: MDSO) for its industry-leading electronic data capture (EDC) and clinical data management (CDM), safety data capture and reporting, and medical coding solutions. A member of the Zeltia Group and a leader in the development of antitumor drugs of marine origin, PharmaMar said the company’s investment in the Medidata Clinical Cloud™ will efficiently streamline its clinical trial processes in its mission to deliver drugs that treat cancer and rare ("orphan") diseases.
-
Scripps Research Institute Scientists Find Promising New Approach To Preventing Progression Of Breast Cancer
2/15/2013
Doctors currently struggle to determine whether a breast tumor is likely to shift into an aggressive, life-threatening mode—an issue with profound implications for treatment.
-
Portola And Lee's Pharmaceutical Enter Into Agreement To Expand Phase 3 APEX Study Of Betrixaban Into China
1/29/2013
Portola Pharmaceuticals, Inc. and Lee's Pharmaceutical (HK) Ltd. (
HKSE : 0950) today announced an agreement to jointly expand the Phase 3 APEX study of betrixaban into China, with an option for Lee's to negotiate for the commercial rights to the drug in China. -
Amgen Announces Top-Line Results Of Phase 3 Aranesp® (darbepoetin alfa) RED-HF® Trial
1/17/2013
Amgen (NASDAQ:AMGN) today announced top-line results of the Phase 3 Aranesp® (darbepoetin alfa) RED-HF® (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.
-
ActiGraph Launches ActiLife Mobile App
1/14/2013
ActiGraph, a leading provider of objective patient monitoring solutions for the global research community, recently announced the release of a new mobile app for researchers.
-
GeoVax Announces Enrollment Completion For Phase 1/2 Clinical Trial For HIV/AIDS Therapeutic Vaccine
1/10/2013
GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and treat HIV/AIDS, announced it has completed enrollment in a nine-patient Phase 1/2 clinical trial testing the safety, immunogenicity and ability of its DNA/MVA vaccine to elicit protective immune responses in HIV-infected individuals.
-
Gradalis, Inc. Closes $24M In Series B Financing To Advance Late-Stage Trials Of FANG™ Personalized Cancer Vaccine
1/3/2013
Gradalis, Inc. today announced that is has closed a $24 million Series B round of financing. Gradalis will use the funding to advance its autologous vaccine platform, FANG™, through late-stage clinical trials and expand manufacturing capabilities to accommodate commercial launch of FANG.